Ex-PRESS device exposure warning

Article

With increasing numbers of patients undergoing filtration surgery with the Ex-PRESS Miniature Glaucoma devices (Optonol), anterior segment surgeons should be aware of the potential for device exposure.

With increasing numbers of patients undergoing filtration surgery with the Ex-PRESS Miniature Glaucoma devices (Optonol), anterior segment surgeons should be aware of the potential for device exposure, according to a case series reported in the December 2007 issue of the Journal of Glaucoma.

Joshua Stein and colleagues from Duke University, North Carolina, USA conducted a retrospective chart review to identify all patients who were referred for Ex-PRESS miniature glaucoma device exposure between January 2004 and December 2005.

A total of six patients (eight eyes) experienced device exposure, with an average time to exposure of 8.5 months. In two eyes, the shunt had been inserted under a half-thickness flap. In both these eyes and in one additional eye, Mitomycin-C had been used during shunt insertion. In five eyes, visual acuity worsened after the device was removed and all eight patients required concomitant glaucoma surgery with device removal.

The authors of this report suggest that anterior segment surgeons should be aware of the possibility of device exposure when using the Ex-PRESS.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.